Aclarubicin

Aclarubicin
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • (1S,2S,4R)-Methyl 4-(((2S,5R,6R)-4-(dimethylamino)-5-(((1S,3R,4S)-3-hydroxy-5-methyl-4-(((2S,6R)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.055.277 Edit this at Wikidata
Chemical and physical data
FormulaC42H53NO15
Molar mass811.878 g·mol−1
3D model (JSmol)
Melting point151 to 153 °C (304 to 307 °F) (decomposes)
  • CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
  • InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3 checkY
  • Key:USZYSDMBJDPRIF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable.

However, it has subsequently been reevaluated[3] due to possible advantages over other chemotherapeutic drugs in the treatment of certain cancers such as acute myeloid leukemia.[4][5]

Soil bacteria Streptomyces galilaeus can produce aclarubicin.

It can induce histone eviction from chromatin upon intercalation.[6][7]

References

  1. ^ CID 451415 from PubChem
  2. ^ Jensen PB, Jensen PS, Demant EJ, Friche E, Sørensen BS, Sehested M, et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Research. 51 (19): 5093–5099. PMID 1655244.
  3. ^ Amsen E (27 July 2024). "One man's mission to revive a forgotten, life-saving cancer drug". The Guardian.
  4. ^ Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D (November 2011). "A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome". Journal of Hematology & Oncology. 4: 46. doi:10.1186/1756-8722-4-46. PMC 3230125. PMID 22082134.
  5. ^ Murzyn A, Orzeł J, Obajtek N, Mróz A, Miodowska D, Bojdo P, et al. (July 2024). "Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing". Cancer Chemotherapy and Pharmacology. 94 (2): 123–139. doi:10.1007/s00280-024-04693-1. PMC 11390774. PMID 38965080.
  6. ^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. Bibcode:2013NatCo...4.1908P. doi:10.1038/ncomms2921. PMC 3674280. PMID 23715267.
  7. ^ Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J (July 2015). "Chemical profiling of the genome with anti-cancer drugs defines target specificities". Nature Chemical Biology. 11 (7): 472–480. doi:10.1038/nchembio.1811. PMID 25961671.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.